Key Takeaways Aurora's fiscal Q1 revenues rose 17% year over year to C$98 million, led by medical cannabis growth.Medical cannabis sales climbed 37%, boosting adjusted EBITDA by 209% and free cash flow by 42% in Q1.Weak recreational sales and heavy competition temper optimism despite stronger medical performance.Shares of Aurora Cannabis (ACB) have risen 21% year to date, outperforming the industry’s 5% rise, as seen in the chart below.Image Source: Zacks Investment ResearchIn recent months, President Trump ...